Universal Beteiligungs und Servicegesellschaft mbH bought a new position in The Chemours Company (NYSE:CC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,857 shares of the specialty chemicals company’s stock, valued at approximately $174,000.
Several other institutional investors and hedge funds have also bought and sold shares of CC. Bank of Montreal Can boosted its position in Chemours by 1,496.4% in the fourth quarter. Bank of Montreal Can now owns 953,240 shares of the specialty chemicals company’s stock worth $16,110,000 after purchasing an additional 893,530 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Chemours by 23.8% in the fourth quarter. Ameriprise Financial Inc. now owns 4,373,172 shares of the specialty chemicals company’s stock worth $73,907,000 after purchasing an additional 839,849 shares during the last quarter. Millennium Management LLC boosted its position in Chemours by 44.6% in the fourth quarter. Millennium Management LLC now owns 2,507,262 shares of the specialty chemicals company’s stock worth $42,373,000 after purchasing an additional 773,537 shares during the last quarter. Invesco Ltd. boosted its position in Chemours by 141.5% in the fourth quarter. Invesco Ltd. now owns 1,020,001 shares of the specialty chemicals company’s stock worth $17,238,000 after purchasing an additional 597,638 shares during the last quarter. Finally, Covalis Capital LLP purchased a new position in Chemours in the fourth quarter worth about $8,768,000. 76.26% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Barclays decreased their price objective on Chemours from $16.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 28th. Mizuho raised their price objective on Chemours from $13.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Wall Street Zen downgraded Chemours from a “hold” rating to a “sell” rating in a research note on Wednesday, May 21st. Morgan Stanley decreased their price objective on Chemours from $22.00 to $15.00 and set an “equal weight” rating on the stock in a research note on Monday, May 12th. Finally, UBS Group decreased their price objective on Chemours from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $17.44.
Chemours Stock Up 3.2%
Shares of CC opened at $12.60 on Wednesday. The business’s 50 day moving average is $12.10 and its 200 day moving average is $13.41. The company has a market capitalization of $1.89 billion, a PE ratio of 63.00 and a beta of 1.61. The Chemours Company has a 12-month low of $9.13 and a 12-month high of $22.38. The company has a current ratio of 1.75, a quick ratio of 0.83 and a debt-to-equity ratio of 7.01.
Chemours (NYSE:CC – Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.12. The company had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a return on equity of 23.82% and a net margin of 0.54%. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the company earned $0.38 EPS. Research analysts expect that The Chemours Company will post 2.03 earnings per share for the current fiscal year.
Chemours Announces Dividend
The company also recently declared a dividend, which was paid on Monday, June 16th. Shareholders of record on Monday, May 19th were issued a dividend of $0.0875 per share. This represents a yield of 317.0%. The ex-dividend date was Friday, May 16th. Chemours’s dividend payout ratio (DPR) is currently 175.00%.
Insider Activity at Chemours
In other news, insider Damian Gumpel purchased 13,400 shares of the business’s stock in a transaction on Monday, June 2nd. The stock was acquired at an average price of $9.22 per share, for a total transaction of $123,548.00. Following the acquisition, the insider directly owned 123,879 shares of the company’s stock, valued at $1,142,164.38. This represents a 12.13% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Shane Hostetter purchased 4,450 shares of the business’s stock in a transaction on Monday, May 19th. The shares were purchased at an average price of $11.28 per share, with a total value of $50,196.00. Following the acquisition, the chief financial officer directly owned 59,694 shares in the company, valued at $673,348.32. This represents a 8.06% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 25,672 shares of company stock valued at $251,573 in the last 90 days. 0.34% of the stock is currently owned by company insiders.
About Chemours
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.
Read More
- Five stocks we like better than Chemours
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Unusual Machines: A Speculation With Tailwinds to Lift Its Price
- How to invest in marijuana stocks in 7 steps
- Zebra Technologies: Riding the Automation Wave to Profits
- Roth IRA Calculator: Calculate Your Potential Returns
- Vertical Aerospace’s New Deal and Earnings De-Risk Production
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.